News
Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback